α-Emitting cancer therapy using 211 At-AAMT targeting LAT1.

α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with 211 At-labeled α-methyl-l-tyrosine (211 At-AAMT) as a carrier of 211 At into tumors. 211 At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of 211 At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse 211 At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse 211 At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that 211 At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy. © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Citation

Kazuko Kaneda-Nakashima, ZiJian Zhang, Yoshiyuki Manabe, Atsushi Shimoyama, Kazuya Kabayama, Tadashi Watabe, Yoshikatsu Kanai, Kazuhiro Ooe, Atsushi Toyoshima, Yoshifumi Shirakami, Takashi Yoshimura, Mitsuhiro Fukuda, Jun Hatazawa, Takashi Nakano, Koichi Fukase, Atsushi Shinohara. α-Emitting cancer therapy using 211 At-AAMT targeting LAT1. Cancer science. 2021 Mar;112(3):1132-1140

Mesh Tags

Substances

PMID: 33277750

search → result